adverse action against the individual, as required by 5 U.S.C. 552a(p).
4. Report the matching program to Congress and the OMB, in advance and annually, as required by 5 U.S.C. 552a(o) (2)(A)(i), (t), and (u)(3)(ID).
5. Publish advance notice of the matching program in the Federal Register as required by 5 U.S.C. 552a(e)(12).

This matching program meets these requirements.

Barbara Demopulos,
Privacy Advisor, Division of Security, Privacy Policy and Governance, Office of Information Technology, Centers for Medicare & Medicaid Services.

Participating Agencies
The Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS) is the recipient agency, and the Department of Homeland Security (DHS), United States Citizenship and Immigration Services (USCIS) is the source agency.

Authority for Conducting the Matching Program
The principal authority for conducting the matching program is 42 U.S.C. 18001 et seq.

Purpose(s)
The matching program will provide CMS with USCIS data which CMS and state-based administering entities will use to determine individuals’ eligibility for initial enrollment in a Qualified Health Plan through an Exchange established under the Patient Protection and Affordable Care Act, for Insurance Affordability Programs (IAPs), and for certificates of exemption from the shared responsibility payment; and to make eligibility redeterminations and renewal decisions, including appeal determinations. IAPs include:
1. Advance payments of the premium tax credit (APTC) and cost sharing reductions (CSRs),
2. Medicaid,
3. Children’s Health Insurance Program (CHIP), and
4. Basic Health Program (BHP).

Categories of Individuals
The individuals whose information will be used in the matching program are consumers (applicants and enrollees) who receive the eligibility determinations and redeterminations described in the preceding Purpose(s) section.

Categories of Records
The categories of records used in the matching program are identity, citizenship, and immigration status records. The data elements are described below.
To request information from USCIS, CMS will submit a file to SSA that contains the following mandatory data elements: Last Name; First Name; Middle Name; Date of Birth; One or More Immigration Number(s) (e.g., Alien Registration/USCIS Number, Arrival-Departure Record I–94 Number, SEVIS ID Number, Certificate of Naturalization Number, Certificate of Citizenship Number, or Unexpired Foreign Passport Number); and Other Information From Immigration Documentation (e.g., Country of Birth, Date of Entry, Employment Authorization Category).

When USCIS is able to match the information provided by CMS, USCIS will provide CMS with the following about each individual, as relevant: Last Name; First Name; Middle Name; Date of Birth; One or More Immigration Number(s) (e.g., Alien Registration/USCIS Number, Arrival-Departure Record I–94 Number, SEVIS ID Number, Certificate of Naturalization Number, Certificate of Citizenship Number, or Unexpired Foreign Passport Number); and Immigration class of admission and/or employment authorization); Sponsorship Data (e.g., name, address, and social security number of Form I–864/I–864EZ sponsors and Form I–864A household members, when applicable); and Case Verification Number.

System(s) of Records
The records used in this matching program are disclosed from the following systems of records, as authorized by routine uses published in the System of Records Notices (SORNs) cited below:
A. System of Records Maintained by CMS
CMS Health Insurance Exchanges System (HIX), System No. 09–70–0560, last published in full at 78 FR 63211 (Oct. 23, 2013), and amended at 83 FR 6591 (Feb. 14, 2018). Routine use 3 supports CMS’ disclosures to USCIS for use in this matching program.
B. System of Records Maintained by USCIS
DHS/USCIS–004 Systematic Alien Verification for Entitlements Program, 85 FR 31798 (May 27, 2020). Routine use 1 permits USCIS’ disclosures to CMS.

[FR Doc. 2021–05192 Filed 3–11–21; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families

Proposed Information Collection Activity; Title IV–E Programs Quarterly Financial Report (OMB No: 0970–0205)

AGENCY: Children’s Bureau, Administration on Children, Youth and Families, Administration for Children and Families, HHS.

ACTION: Request for public comment.

SUMMARY: The Administration for Children and Families (ACF) is requesting a 3-year extension of the form CB–496: Title IV–E Programs Quarterly Financial Report. This form is currently approved under the ACF Generic Clearance for Financial Reports (OMB #0970–0510, expiration 5/31/2021), and ACF is proposing to reinstate the previous OMB number under which this form had been approved (OMB # 0970–0205). There are no substantial changes requested to the form.

DATES: Comments due within 60 days of publication. In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

ADDRESSES: Copies of the proposed collection of information can be obtained and comments may be forwarded by emailing infocollection@acf.hhs.gov. Alternatively, copies can also be obtained by writing to the Administration for Children and Families, Office of Planning, Research, and Evaluation (OPRE), 330 C Street SW, Washington, DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection.

SUPPLEMENTARY INFORMATION:
Description: Form CB–496 Parts 1–3 is a financial report submitted following the end of each fiscal quarter by each state or tribe with an approved title IV–E plan administering any of five title IV–E entitlement grant programs—Foster Care, Adoption Assistance, Guardianship Assistance, Prevention Services, or Kinship Navigator. Part 4 of form CB–496 is an annual submission associated with the Adoption Assistance program on the calculation of adoption savings under section 473(e) of the Social Security Act, along with an accounting of the amount of expenditure of any such savings. It is required from each state or tribe with an approved title IV–E plan administering the Adoption Assistance Program. There
are no substantial changes to the forms, only minor changes such as to reflect a temporary change in the Federal Financial Participation rate.

**Annual Burden Estimates**

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Total number of respondents</th>
<th>Annual number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form CB–496</td>
<td>..........................................................</td>
<td>67</td>
<td>4</td>
<td>23</td>
</tr>
</tbody>
</table>

**Estimated Total Annual Burden Hours:** 6,164.

**Comments:** The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

**Authority:** 42 U.S.C. 671(a)(6), 42 U.S.C. 671(a)(7), 42 U.S.C. 673(a)(8)(B), and 42 U.S.C. 674(a) and (b).

Mary B. Jones,
ACE/OPRE Certifying Officer.
[FR Doc. 2021–05157 Filed 3–11–21; 8:45 am]
BILLING CODE 4184–25–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2020–N–0026]

**Issuance of Priority Review Voucher; Rare Pediatric Disease Product**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA), authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria.

FDA is required to publish notice of the award of the priority review voucher. FDA has determined that NULIBRY (fosdenopterin), manufactured by Origin Biosciences, Inc., meets the criteria for a priority review voucher.

**FOR FURTHER INFORMATION CONTACT:** Althea Cuff, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–4061, Fax: 301–796–9856, email: althea.cuff@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION:** FDA is announcing the issuance of a priority review voucher to the sponsor of an approved rare pediatric disease product application. Under section 529 of the FD&C Act (21 U.S.C. 360ff), which was added by FDASIA, FDA will award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA has determined that NULIBRY (fosdenopterin), manufactured by Origin Biosciences, Inc., meets the criteria for a priority review voucher.

NULIBRY (fosdenopterin) is indicated to reduce the risk of mortality in patients with Molybdenum Cofactor Deficiency Type A.

For further information about the Rare Pediatric Disease Priority Review Voucher Program and for a link to the full text of section 529 of the FD&C Act, go to http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseases/Conditions/RarePediatricDiseasePriorityVoucherProgram/default.htm. For further information about NULIBRY (fosdenopterin), go to the “Drugs@FDA” website at http://www.accessdata.fda.gov/scripts/cder/daf/.

Dated: March 9, 2021.

Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021–05207 Filed 3–11–21; 8:45 am]
BILLING CODE 4184–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2020–N–1440]

**Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; establishment of a public docket; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

**DATES:** The meeting will be held on April 27, 2021, from 1 p.m. to 3:45 p.m. Eastern Time, on April 28, 2021, from 9 a.m. to 3 p.m. Eastern Time, and on April 29, 2021, from 9 a.m. to 5:30 p.m. Eastern Time.

**ADDRESSES:** Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA–2020–N–1440. The docket will close on April 26, 2021. Submit either electronic or written comments on this public meeting by April 26, 2021. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before April 26, 2021. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time.